Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20231536 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Condition: Cardiovascular Diseases
Interventions: Drug: Telmisartan;   Drug: Combination of Telmisartan and Ramipril;   Drug: Ramipril

Indicates status has not been verified in more than two years